NovoCure Ltd
NovoCure Ltd develops and commercializes Tumor Treating Fields (TTFields) therapy, a non-invasive cancer treatment delivered through portable medical devices and arrays worn by patients. The company is headquartered in the United States and serves oncology markets across the U.S., Europe, Japan, and other international markets through direct and partner-based distribution.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenuePortable tumor-treating field systems used to deliver therapy for approved cancer indications.
Replacement arrays and related consumables used with the therapy devices.
Training, onboarding, and support services that help patients use the therapy at home.
Customers
NovoCure sells primarily to oncology patients through healthcare providers, with therapy adoption driven by physicians who prescribe and certify for use of the system. Its end users include patients with brain, thoracic, and abdominal cancers, while hospitals and distributors are important channels in certain markets such as Japan and Greater China. Reimbursement and physician training are central to customer adoption because the therapy is device-based, home-used, and indication-specific.
Patients with GBM treated with Optune Gio, typically through neuro-oncology and oncology centers.
Patients with non-small cell lung cancer treated with Optune Lua in approved markets.
Patients with pancreatic cancer treated with Optune Pax in the U.S. and other approved markets.
Hospitals and local partners that distribute the product and support patient onboarding in some countries.
Strategy
NovoCure’s strategy centers on expanding adoption of TTFields in approved indications while pursuing additional regulatory approvals and geographic expansion. The company also relies on physician training, patient support, and collaboration partners to scale commercialization in complex oncology markets. Its longer-term direction is to broaden the addressable cancer set beyond CNS and lung while maintaining access through reimbursement and channel partnerships.
Revenue depends on patient starts and continued use of TTFields therapy.
New indications and reimbursement pathways expand the addressable market.
The therapy requires physician certification and local market execution.
Geography
Q1/2026NovoCure is a U.S.-based company with revenue generated across the United States and a broad international footprint, including France, Germany, Japan, Greater China, and other markets. The company’s disclosures show meaningful revenue contribution from Europe and other international markets, while Greater China is served through a licensing and collaboration structure with Zai. Geography matters because reimbursement, regulatory approvals, and channel design differ by market and directly affect adoption.
Share of the revenue the company reports by geography.
Risks
NovoCure is exposed to regulatory, reimbursement, and commercialization risk because its products require approval, physician training, and payer access in each market. The business also depends on a small number of core products, single-source suppliers for some components, and third-party collaborators in certain geographies, which increases execution and supply-chain sensitivity.
- Concentration in a small number of productsImpact: HighLikelihood: Medium
Business prospects depend heavily on a few approved TTFields indications.
Exposure - Regulatory and reimbursement delaysImpact: HighLikelihood: Medium
Adoption depends on approvals and payer coverage in each market.
Exposure: New indications and international expansion
- Single-source supply dependenceImpact: HighLikelihood: Low
Loss of a supplier could delay shipments or clinical studies.
Exposure: Components and manufactured parts
- Cybersecurity and patient data exposureImpact: MediumLikelihood: Medium
The company handles sensitive patient treatment and health information.
Exposure: Connected therapy systems and third-party hosting
- Partner execution riskImpact: MediumLikelihood: Medium
Some markets rely on collaborators that control commercialization efforts.
Exposure: Greater China and selected distribution markets
Accounting
Judgemental itemsRevenue depends on product delivery, reimbursement-related claims, and collaboration arrangements.
Impact: Can affect timing and comparability of reported revenue
Specialized arrays and device components may require write-downs if demand or design changes.
Impact: Affects cost of revenues and gross margin
Reusable patient equipment is tracked and depreciated/leased over time.
Impact: Affects balance sheet assets and operating expenses
Device technology and usage patterns can change, triggering impairment reviews.
Impact: May create non-cash charges
The company operates across jurisdictions with different tax rules.
Impact: Can change tax expense and liabilities
Similar listed companies
Publicly listed companies with a comparable business focus.
NextCure, Inc.
NXTC · Pharmaceutical Preparations
OnKure Therapeutics, Inc.
OKUR · Pharmaceutical Preparations
NovaBridge Biosciences
NBP · Pharmaceutical Preparations
NovaBridge Biosciences is a global biotechnology company focused on discovering, developing, and partnering around differentiated therapeutic candidates in oncology and ophthalmology.
Exicure, Inc
XCUR · Pharmaceutical Preparations
NeOnc Technologies Holdings, Inc
NTHI · Pharmaceutical Preparations
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Last updated: 24/09/2026